Penny Stock Below Rs 2 To Consider Proposal For Bonus Issue, Stock Split & Dividend

Penny stock priced under Rs 2, Earum Pharmaceuticals Ltd is scheduled to hold a meeting on July 14, 2023 to consider the proposal for bonus issue and stock split, according to its BSE filing dated June 27, 2023. The company will also consider the proposal for buyback of equity shares in its upcoming meeting on July 14. It also informed in its regulatory filing that the proposal to recommend declaration for dividend will also be considered for financial year 2022-23. Check details below:

Earum Pharmaceuticals Ltd To Consider Sub-Division of Shares, Bonus Shares, Dividend, & Buyback of Equity Shares: As per its BSE filing, "Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of the Company will be held on Friday, 14th July, 2023 at 11:00 A.M. at the Registered Office of the Company situated at A-1106, Empire Business Hub Near AUDA Water Tank, Science City Road, Sola, Ahmedabad - 380060, to discuss and consider inter alia:

• The proposal for Buyback of Equity Shares of the Company.
• The proposal to recommend the declaration of Final Dividend for the F.Y. 2022-23.
• The proposal of Issue of Bonus Equity Shares to the existing equity Shareholders of the Company.
• The proposal of sub-division of equity shares of the Company.
• To finalize the date, day, time and venue of Annual General Meeting of shareholders for the F.Y. 2022-23.

Earum Pharmaceuticals Stock Outlook & Return: The current market price of Earum Pharmaceuticals stock is Rs 1.68 apiece with intraday fall of 2.33% on BSE. Its 52-week high price is Rs 3.68 per share and 52-week low price is Rs 1.52 per share, respectively. The company has a market capitalisation of Rs 41.51 crore.
The stock in last 6-months declined 28%, fell 45% in last 1-year, and tumbled 66% in last 2-years.

Earum Pharmaceuticals Financial Outlook: The company for the quarter ended March 31, 2023 declared its standalone total income at Rs 1.53 crore, down 40.20 % as compared to its previous quarter total income of Rs 2.56 crore. It announced its net profit after tax for latest quarter at Rs .26 crore.

Earum Pharmaceuticals About: It is engaged in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical formulation products. These products are anti-biotic drugs, anti-malarial drugs, anti-allergic & anti cold drugs, analgesic/ anti-pyretic & anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastro intestinal drugs, steroids, gynecology drugs, calcium, multivitamins, anti-oxidants and injections, according to its official website.

Disclaimer: The stock just highlights the dividend, bonus share, and stock split and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for ay losses. Please consult a professional advisor.